Objectives: To identify biomarkers predicting prognosis in bladder cancer patients undergoing the gemcitabine and cisplatin regimen. Methods: We studied 52 patients with metastatic bladder cancer treated with the gemcitabine and cisplatin regimen by evaluating the relationship between the expression of two biomarkers, ribonucleotide reductase subunit M1 and excision repair cross complementing 1, by immunohistochemistry and clinical outcomes. Results: The patients with low expression of ribonucleotide reductase subunit M1 showed a higher objective response rate by the gemcitabine and cisplatin regimen than those with high expression of ribonucleotide reductase subunit M1 (80.0% and 45.5%, respectively). No differences were observed according to the expression level of excision repair cross complementing 1. Low expression of ribonucleotide reductase subunit M1 significantly prolonged overall survival and progression-free survival compared with the high expression group. Low expression of excision repair cross complementing 1 tended to prolong overall survival and progression-free survival, but there were no significant differences (P = 0.07 and 0.10, respectively). Multivariate analysis showed that the expression of ribonucleotide reductase subunit M1 was the only independent prognostic factor (P = 0.012). Conclusions: The expressions of ribonucleotide reductase subunit M1 seem to be associated with clinical response and survival in patients with metastatic bladder cancer treated with gemcitabine and cisplatin-based chemotherapy.
Introduction
Metastatic bladder cancer is generally associated with poor prognosis, even if various treatment modalities have been carried out. Systemic combination cytotoxic chemotherapy remains the mainstay for unresectable locally advanced and/or metastatic UC as the primary treatment. GC became the new standard treatment for metastatic UC based on randomized trials showing similar survival with GC and MVAC, although there is a more favorable toxicity profile for GC.
1,2 However, systemic chemotherapies for advanced bladder cancer have reached a peak for survival improvement. Identification of biomarkers that can predict treatment sensitivity and clinical outcomes to gemcitabine-containing chemotherapies in advanced UC would therefore be of great value for therapeutic decision-making. 3 We recently showed that high expression levels of hENT1 protein, required for efficient uptake of gemcitabine into cytoplasm, was an independent prognostic marker as a positive regulator in patients with metastatic bladder cancer treated using gemcitabine-containing systemic chemotherapy. 4 However, there could be limitations in predicting clinical outcomes using only one biomarker. As such, the use of two or more biomarkers is preferred for more accurate prediction.
RRM1 could also serve as a potential biomarker, as one recent study showed that it could be a crucial predictor of non-small cell lung carcinoma response to gemcitabine + platinum chemotherapy. 5, 6 In the present study, we have focused on RRM1 as a promising candidate molecule that associates with the acquisition of resistance to gemcitabine. In contrast, ERCC1 is a key molecule that associates with resistance to cisplatin-related chemotherapy, as it plays a restricting role in the nucleotide excision repair mechanism. It was reported to be correlated with tolerance to cisplatin-containing chemotherapy for advanced bladder cancer. 7 Therefore, we aimed to evaluate the effectiveness of RRM1and ERCC1 as biomarkers in advanced bladder cancer patients who underwent chemotherapy including gemcitabine as well as cisplatin.
Methods Patients
We reviewed the clinical databases of 52 patients with metastatic bladder cancer who underwent chemotherapy including gemcitabine as well as cisplatin at the Wakayama Medical University between May 2002 and April 2012. All 52 patients fulfilled the following inclusion criteria: (i) histologically verified UC; (ii) ECOG PS ≤2; (iii) adequate renal function; (iv) bi-dimensionally measurable disease; and (v) ≥2 cycles of chemotherapy containing gemcitabine and cisplatin were carried out. The primary end-point in this research was OS, and secondary end-points were PFS and clinical responses. These study protocols were licensed by the ethics review board (IRB approval number W.M.U. No. 34).
A total of 29 patients underwent GC chemotherapy (gemcitabine 1000 mg/m 2 and cisplatin 70 mg/m 2 on day 1, followed by gemcitabine 1000 mg/m 2 on days 8 and 15) every 4 weeks. 1 The remaining 23 patients received GCT (gemcitabine 1000 mg/m 2 and paclitaxel 80 mg/m 2 on days 1 and 8 plus cisplatin 70 mg/m 2 on day 1) every 3 weeks. 8 Patients received the treatment until unacceptable toxicity or disease progression occurred. Clinical responses were measured by imaging after at least two cycles based on the RECIST criteria. The best clinical responses were retrieved from the electronic medical charts. Survival time was calculated from the date of initial chemotherapy to the relevant event or censoring.
Immunohistochemistry
We collected bladder tumor tissue before the patients underwent chemotherapy. For immunostaining, deparaffinized sections were placed in a solution containing 3% hydrogen peroxide and 97% methanol followed by treatment with Target Retrieval Solution High pH (Dako Japan, Tokyo, Japan). The slides were incubated with 1:100 dilutions of anti-RRM1 monoclonal antibody (Protein Tech Group, Chicago, IL, USA) or 1:200 dilutions of monoclonal ERCC1 mouse antibody (Spring Bioscience Inc., Pleasanton, CA, USA) in a humidified chamber at 4°C overnight. The slides were then reacted with horseradish peroxidase conjugated second antibody, and developed with diaminobenzidine solution (Nihirei, Tokyo, Japan). Immunohistochemical scoring was carried out in a blinded manner by a pathologist (YN) who had no clinical data. The expression level of RRM1 was measured by the proportion of stained cells and staining degree as previously described. 5, 9 Staining degree was graded as follows: 0, absent; 1+, positive, but weaker than positive control; 2+, as strong as positive control; and 3+, stronger than positive control. When more than half of the tumor cells were stained with staining degree 3+, we determined the tumor as high expressions of RRM1. Scoring for ERCC1 staining was calculated as previously described. 10 Briefly, semiquantitative Hscore was calculated by the multiplying intensity score (staining intensity of cell nuclei, 0-3) and proportion score (percentage of positive cells, 0, 0.1, 0.5, 1.0). When the H-score was ≥1.5, the tumor was considered as a high expression of ERCC1. The same method was used for the negative control, except for specific primary antibodies. Human colonic adenocarcinoma and tonsil tissues were used as positive controls for RRM1 and ERCC1, respectively.
Statistical analysis
The relationship between RRM1, ERCC1 expression and clinical outcome was evaluated by Pearson's v 2 -test and Fisher's exact test. PFS and OS were estimated by the KaplanMeier method, and statistical differences among groups were examined by the log-rank test. We carried out univariate and multivariate analyses using the Cox proportional hazards regression model to verify the prognostic values of RRM1 and ERCC1. A two-tailed P < 0.05 was taken to show statistical significance for all analyses, and all confidence intervals were 95%. JMP pro version 11.0.0 software (SAS Institute, Cary, NC, USA) was used for statistical analysis.
Results
Baseline characteristics for all 52 patients according to RRM1 and ERCC1 expression are shown in Table 1 . The median age was 69.5 years (range 35-88 years), and 45 patients (86.5%) were men. A total of 37 patients (71.2%) had a PS of 0, whereas 15 (28.8%) had a PS of 1 or 2. Visceral metastases (bone, liver or lung diseases) were found in 24 patients (46.2%), and only lymph node metastases were seen in 28 patients (53.8%). Based on the Bajorin risk criteria (ECOG PS ≥2 with the presence of visceral metastases), the number of the patients in the low-risk group (0 risk factor), intermediate-risk group (1 risk factor) and high-risk group (2 risk factors) were 22, 21 and 9, respectively. 11 The median number of cycles of GC and GCT were three (range [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and four (range 3-7), respectively. the overall response rate of GC and GCT chemotherapy was 65.4%. The median follow-up time was 16.6 months (range 4.0-98.0 months), and the median OS was 16.6 months (range 13.6-19.3 months). At this point (November 2015), five patients (9.6%) survived, five patients (9.6%) were censored, 41 (78.8%) died from bladder cancer and one (1.9%) died from another cause.
RRM1 was expressed in the cytoplasm of bladder cancer cells by immunohistochemistry. A total of 22 of 52 samples (42.3%) showed high RRM1 immunoreactivity (intensity scores 3+ in ≥50% of tumor cells). The remaining 30 samples (57.7%) showed weak signals for RRM1 with various proportions from 10% to 100%. In contrast to RRM1, ERCC1 was expressed in the nuclei of tumor cells. As the mean H-score was 1.45, H-score ≥1.5 was defined as high expression. Out of 52 patients, 27 (51.9%) who had tumors were determined to have high expression of ERCC1. The remaining 25 (48.1%) samples were categorized as low expression. Age, sex, ECOG PS, presence of visceral metastases, Bajorin Risk Group and chemotherapy regimen were similar between the low and high expression of RRM1, as well as ERCC1 expression (Table 1) . However, RRM1 and ERCC1 expression trended toward lower expression in patients who had undergone radical cystectomy (P = 0.02 and 0.03, respectively).
Representative immunohistochemical findings showing weak or strong expressions of RRM1 and ERCC1 are presented in Figure 1 . Table 2 shows the clinical response according to the expression levels of RRM1 and ERCC1. Although the patients with low expression of RRM1 showed better clinical response (80.0%) compared with those with high expression Table 1 Patients' characteristics according to RRM1 and ERCC1 expression of RRM1 (45.5%), no significant difference regarding clinical response was observed between the low ERCC1 group (64.0%) and high ERCC1 group (66.7%).
Median OS was significantly shorter in patients with high RRM1 expression than in patients with low RRM1 expression (13.6 months vs 23.0 months, P = 0.0016; Fig. 2a ). Median PFS was significantly shorter in patients with high RRM1 expression than in patients with low RRM1 expression (7.4 months vs 15.2 months, P = 0.0017; Fig. 2b ).
For ERCC1, the high ERCC1 expression group showed shorter median OS than the low ERCC1 expression group (15.5 months vs 19.9 months, Fig. 2c ), although there was no significant correlation (P = 0.069). Similarly, the high ERCC1 expression group showed shorter median PFS than the low ERCC1 expression group (10.7 months vs 13.4 months; Fig. 2d ), although there was no significant correlation (P = 0.1). Table 3 represents univariate and multivariate Cox regression analyses to predict OS. We chose age, sex, ECOG PS, presence of visceral metastasis, history of radical cystectomy and chemotherapy regimen as variables. The expression of ERCC1 and RRM1 were also included in the variables. According to univariate analysis, ECOG PS (P = 0.03) and RRM1 expression (P = 0.003) were identified as useful prognostic factors for OS. Additionally, RRM1 expression was the only independent prognostic marker for OS by multivariate analysis (P = 0.012).
Discussion
GC became the new standard treatment for metastatic UC, as it showed similar survival outcomes with favorable toxicity compared with MVAC in a large cohort randomized trial. 1, 2 Even though novel systemic therapy showing better clinical outcome than GC or MVAC has yet to be clarified, GC and MVAC have been widely used. In order to decide between GC and MVAC, biomarkers that can predict clinical benefits of these chemotherapies are desirable. Such biomarkers can also be applied to deciding between GC and MVAC in a neoadjuvant setting. These biomarkers are substances involved in the pharmacokinetics of chemotherapeutic agents, and we have focused on such molecules in the present study.
3,12,13 hENT1 is the major nucleoside transporter protein required for efficient uptake of gemcitabine into cytoplasm. High expression of hENT1 facilitates efficient delivery of gemcitabine into tumor cells. We antecedently reported that high expression of hENT1 could be a useful biomarker for the bladder cancer patients who underwent GC chemotherapy. 4 In that study, we also evaluated the expression of ERCC1. ERCC1 is the nucleotide excision repair enzyme involved in resistance to cisplatin. Although the median survival time of patients with high ERCC1 expression is shorter than that of those with low ERCC1 expression, the difference did not reach statistical significance. In the present study, we studied the usefulness of RRM1 as a biomarker. RRM1 is a regulatory subunit of ribonucleotide reductase required for deoxynucleotide production, a crucial step in DNA synthesis and repair. The metabolic product of gemcitabine (gemcitabine diphosphate) binds to the substrate-binding site and inactivates the RRM1 subunit, and overexpression of RRM1 invalidates gemcitabine. Therefore, it has been reported that RRM1 could be a predictive marker as a negative regulator after gemcitabine-containing chemotherapy treatment for NSCLC and pancreatic cancer. 14, 15 In the present study, we also clearly showed that high expression of RRM1 is related to shorter survival time in metastatic bladder cancer patients treated with GC or GCT chemotherapy. We have also reevaluated ERCC1 with an increased number of patients. Although the same tendency was observed in our previous result, the difference was not statistically significant.
With regard to expression of RRM1 in urothelial tumors, several studies have been reported with various differences among the investigations. In 2007, Bellmunt et al. measured the expression level of breast cancer 1, ERCC1, RRM1 and caveolin-1 using RT-PCR in 57 patients with advanced or metastatic bladder cancer treated using either GC or GCT. 7 Although a trend towards shorter time to progression was observed in patients with tumors expressing high levels of these four markers, only high expression of ERCC1 was identified as an independent factor associated with worse OS.
In 2010, Harshman et al. targeted 84 patients who underwent radical cystectomy, and measured RRM1 expression in radical cystectomy specimens using the immunohistochemical method. 16 However, no descriptions were provided regarding the use of chemotherapy in these patients. The result shows that tumoral RRM1 expression levels did not correlate with OS for the entire cohort. However, when age was adjusted, high tumoral RRM1 expression in younger patients (aged <70 years) correlated with increased survival. Although the use of chemotherapy in that study was unclear, the result opposed to that of a previous report by Bellmunt et al. In fact, RRM1 is deemed to have two opposite actions on cancer cells. As RRM1 plays an important role in DNA synthesis and repair, RRM1 might act as a tumor suppressor gene. Zheng et al. evaluated RRM1 and ERCC1 gene expressions in 187 patients with resected early-stage non-small cell lung cancer who were not treated with adjuvant chemotherapy.
14 OS was significantly more increased in patients with high RRM1 expression than in those with low RRM1 expression (>120 vs 60.2 months, P = 0.02). In UC, Shilkrut et al. reported that RRM1 expression, but not ERCC1 expression, was identified as a prognostic marker for poor cancer-specific survival in all patients and in those treated with gemcitabine-based regimens and radiotherapy. 17 However, they described that no independent prognostic factor was identified in the multivariate model, which included tumor stage, vascular invasion, hydronephrosis and RRM1 status. Recently, Kim et al. reported high RRM1 expression was significantly associated with shorter PFS and OS in patients with advanced UC treated with GC-based chemotherapy. 18 In the present study, we also showed that high RRM1 expression was associated with poorer prognosis in patients with advanced bladder cancer. In contrast, Bellmunt et al. reported that high expression of ERCC1 was identified as an independent factor associated with worse OS. The Table 3 , we compared the results of RRM1 and ERCC1 expression in patients with advanced UC patients. The present study and that of Kim et al. were almost identical, and showed that RRM1, but not ERCC1, was the independent predictive marker for poor prognosis. Contrary to that, Bellmunt et al. showed that ERCC1, but not RRM1, was the independent predictive marker for poor prognosis. This difference could be explained due to methodological differences (RT-PCR vs immunohistochemistry) and insufficient sample size in both studies, as the number of the metastatic bladder cancer patients was relatively low.
Although the present results were almost identical to those of Kim et al., there were several differences regarding the objectives. In the study by Kim et al., the patient cohort was rather heterogeneous, as 32 patients (60.4%) and 21 patients (39.4%) had bladder and upper UC, respectively. Furthermore, they retrieved the specimens from the primary site of the tumor and metastasized lymph nodes in 35 patients (66.0%) and 18 patients (34.0%), respectively. In contrast, our objectives were focused on bladder cancer patients, and we retrieved specimens from the primary bladder tumor in all patients before initiating chemotherapy. Thus, we targeted more homogeneous objects compared with Kim et al. We believe that the present results can also be applied to the selection of GC or MVAC in the neoadjuvant setting.
Various limitations should be considered when interpreting this study. First, this was a retrospective design with a rather small sample size. In addition, two kinds of chemotherapies, such as without (GC) or with paclitaxel (GCT), were included, although both of them were GCbased chemotherapy. To overcome these limitations, a prospective trial evaluating multiple biomarkers with a large cohort is warranted. Currently, we are carrying out a prospective clinical trial searching for candidates of biomarkers that include RRM1, hENT1, ERCC1 by IHC as well as reverse transcription polymerase chain reaction.
Our data showed that overexpression of RRM1 was correlated with poor prognosis in metastatic bladder cancer patients who underwent gemcitabine-containing chemotherapy. Prospective randomized studies with larger sample size are required to confirm the clinical value of RRM1 as a potential biomarker in bladder cancer patients.
